UroGen Pharma (URGN) GC awarded 32,609 RSUs and sells shares at $19.69
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
UroGen Pharma Ltd. General Counsel Jason Drew Smith reported equity award activity and related share sales. On January 31, 2026, multiple tranches of previously granted restricted stock units (RSUs) vested and were settled into ordinary shares, including awards originally granted in 2023, 2024, and 2025.
That same day, Smith received a new grant of 32,609 RSUs, which will vest in three equal installments on January 31, 2027, January 31, 2028, and January 31, 2029. On February 3, 2026, he sold ordinary shares at $19.69 per share to cover withholding tax obligations arising from the RSU settlements, and continued to hold tens of thousands of UroGen ordinary shares directly after these transactions.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 7,479 shares ($147,262)
Net Sell
10 txns
Insider
Smith Jason Drew
Role
General Counsel
Sold
7,479 shs ($147K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Ordinary Shares | 2,654 | $19.69 | $52K |
| Sale | Ordinary Shares | 1,608 | $19.69 | $32K |
| Sale | Ordinary Shares | 3,217 | $19.69 | $63K |
| Exercise | Restricted Stock Units | 5,500 | $0.00 | -- |
| Exercise | Restricted Stock Units | 3,333 | $0.00 | -- |
| Exercise | Restricted Stock Units | 6,667 | $0.00 | -- |
| Grant/Award | Restricted Stock Units | 32,609 | $0.00 | -- |
| Exercise | Ordinary Shares | 5,500 | $0.00 | -- |
| Exercise | Ordinary Shares | 3,333 | $0.00 | -- |
| Exercise | Ordinary Shares | 6,667 | $0.00 | -- |
Holdings After Transaction:
Ordinary Shares — 52,934 shares (Direct);
Restricted Stock Units — 5,500 shares (Direct)
Footnotes (1)
- Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. The reporting person was granted RSUs on January 31, 2025 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2026. The reporting person was granted RSUs on January 31, 2023 representing 20,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2024. The reporting person was granted RSUs on January 31, 2024 representing 16,500 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2025. 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2027, January 31, 2028 and January 31, 2029.
FAQ
What insider transactions did UroGen Pharma (URGN) report for Jason Drew Smith?
Jason Drew Smith reported RSU vesting, a new RSU grant, and tax-related share sales. Several restricted stock unit awards converted into ordinary shares, a new 32,609-unit RSU grant was issued, and shares were sold at $19.69 solely to satisfy withholding tax obligations.
How many restricted stock units were newly granted to UroGen Pharma’s General Counsel?
Jason Drew Smith received 32,609 new restricted stock units. Each RSU represents one ordinary share. These units were granted on January 31, 2026 and are scheduled to vest in three equal annual installments across January 31, 2027, January 31, 2028, and January 31, 2029.
What is the vesting schedule of the new 32,609 RSU grant at UroGen Pharma?
The 32,609 RSUs vest in three equal annual installments. One-third of the shares underlying this award will vest on each of January 31, 2027, January 31, 2028, and January 31, 2029, aligning compensation with multi-year service at UroGen Pharma.